- HUTCHMED (China) Limited HCM announced initial results from the Phase 3 FRUTIGA study of fruquintinib in combination with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- The study met one of the primary endpoints of statistically significant improvement in progression-free survival (PFS), which is clinically meaningful.
- The other primary endpoint was overall survival (OS). not statistically significant according to the pre-established statistical plan, although there was an improvement in median OS.
- Related: HUTCHMED Cancer Med reduces risk of death from metastatic colorectal cancer by 34%.
- Fruquintinib also demonstrated statistically significant improvement in secondary endpoints, including objective response rate (ORR), disease control rate (DCR), and improved duration of response (DoR).
- The safety profile of fruquintinib in FRUTIGA was consistent with previously reported studies.
- The full and detailed results are being analyzed on an ongoing basis and are expected to be announced at an upcoming scientific meeting. T
- HUTCHMED retains all commercial rights to fruquintinib outside of China. In China, fruquintinib is marketed under the brand name Elunate. HUTCHMED is a partner of Eli Lilly and Co LLY.
- Price promotion: HCM shares are up 15.60% to $11.44 during the premarket session on last check Monday.
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
